Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-099840
Filing Date
2024-08-22
Accepted
2024-08-22 16:09:02
Documents
2
Period of Report
2024-08-20

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3892
2 EX-24.1 alrn-ex24_1.htm EX-24.1 11096
  Complete submission text file 0000950170-24-099840.txt   16526
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Issuer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AILERON THERAPEUTICS, INC. 281 ALBANY STREET CAMBRIDGE MA 02139
Business Address
Aivado Manuel (Reporting) CIK: 0001709603 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38130 | Film No.: 241232076